Lopes MBS, Altermatt HJ, Scheithauer BW, Shepherd CW, VandenBerg SR. Immunohistochemical characteriza-tion of subependymal giant cell astrocytomas. Acta Neu-ropathol 1996;91:368–75. DOI:10.1007/S004010050438
Mei GH, Liu XX, Zhou P, Shen M. Clinical and imag-ing features of subependymal giant cell astrocytoma: Report of 20 cases. Chinese Neurosurg J 2017; 3:1–7. 1DOI:10.1186/S41016-017-0077-4/FIGURES/3
Beaumont TL, Godzik J, Dahiya S, Smyth MD. Sub-ependymal giant cell astrocytoma in the absence of tuber-ous sclerosis complex: case report. J Neurosurg Pediatr. 2015; 16:134–7. DOI:10.3171/2015.1.PEDS13146
Bongaarts A, Giannikou K, Reinten RJ, et al. Subependy-mal giant cell astrocytomas in Tuberous Sclerosis Com-plex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations. Oncotarget 2017; 8:95516–29. DOI:10.18632/ONCOTARGET.20764
Goh S, Butler W, Thiele EA.: Subependymal gi-ant cell tumors in tuberous sclerosis complex. Neu-rology 2004; 63:1457–61. DOI:10.1212/01. WNL.0000142039.14522.1A
Clarke MJ, Foy AB, Wetjen N, Raffel C: Imaging characteristics and growth of subependymal giant cell astrocytomas. Neurosurg Focus. 2006; 20. DOI:10.3171/FOC.2006.20.1.6
Borkowska J, Schwartz RA, Kotulska K, Jozwiak S. Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol. 2011; 50:13–20. DOI:10.1111/J.1365-4632.2010.04727.X
Magri L, Cambiaghi M, Cominelli M, et al. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. Cell Stem Cell. 2011; 9:447–62. DOI:10.1016/J.STEM.2011.09.008
Franz DN, Belousova E, Sparagana S, et al. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS One. 2016, 11. DOI: 10.1371/JOURNAL.PONE.0158476
Roth J, Roach ES, Bartels U, et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 2013, 49:439–44. DOI:10.1016/J.PEDIATRNEU-ROL.2013.08.017
Telfeian AE, Judkins A, Younkin D, Pollock AN, Crino P: Subependymal giant cell astrocytoma with cranial and spinal metastases in a patient with tuberous sclerosis. Case report. J Neurosurg. 2004, 100:498–501. DOI:10.3171/PED.2004.100.5.0498
Aguilera D, Flamini R, Mazewski C, et al. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus. J Pediatr Hematol Oncol. 2014, 36:e448–51. DOI:10.1097/MPH.0000000000000005
Campen CJ, Porter BE: Subependymal giant cell astro-cytoma (SEGA) treatment update. Curr Treat Options Neurol. 2011, 13:380–5. 10.1007/s11940-011-0123-z
Li M, Zhou Y, Chen C, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: A meta-analysis. Orphanet J Rare Dis. 2019, 14:1–9. 10.1186/S13023-019-1012-X/FIGURES/7
Glioblastoma, IDH-wildtype. WHO Classif. tumors on-line, Cent. Nerv. Syst. tumors 5th ed. (2021). Accessed: December 21, 2022. https://tumourclassification.iarc.who. int/chaptercontent/45/7.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23:1231–51. DOI:10.1093/NEUONC/NOAB106